Related Experiment Video
Updated: Jun 26, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[Identification and validation of clinically relevant molecular alterations in prostate cancer]
T Schlomm1, H Sültmann, J Köllermann
1Martini-Klinik, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland. tschlomm@uke.uni-hamburg.de
Abstract:
Significant cellular alterations required for the development and progression of cancers are detectable at the molecular level and represent potential targets for gene-specific therapies. Modern chip techniques allow the parallel analysis of virtually all known human genes and proteins in a single experiment. Using modern high-throughput techniques, numerous potential new biomarkers for the diagnosis and prediction of prostate cancer have been identified. However, so far none of these markers has improved clinical practice. One of the most important challenges in the coming years is the extensive clinical validation of molecular data using clinically relevant end points. For this venture the pivotal prerequisite is the availability of large, comprehensively annotated and standardized high-quality bioresources.
Insights
Molecular alterations in cancer are detectable and offer therapeutic targets. Validating these prostate cancer biomarkers in clinical practice requires high-quality bioresources for accurate diagnosis and treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Context:
- Cancer development involves molecular alterations detectable at the cellular level.
- High-throughput chip techniques enable parallel analysis of human genes and proteins.
- Numerous potential prostate cancer biomarkers have been identified using modern methods.
Purpose:
- To highlight the need for clinical validation of molecular biomarkers.
- To emphasize the importance of high-quality bioresources for advancing cancer research.
- To bridge the gap between molecular data and clinical practice in oncology.
Summary:
- Significant cellular alterations in cancer progression are molecularly detectable and potential targets for gene-specific therapies.
- High-throughput techniques identify numerous potential biomarkers for prostate cancer diagnosis and prediction.
- Extensive clinical validation of molecular data using clinically relevant endpoints is crucial for improving patient care.
Impact:
- Advances in gene-specific therapies for cancer.
- Improved diagnostic and predictive accuracy for prostate cancer.
- Establishment of standardized, high-quality bioresources for clinical validation and research.
